BIOTIE THERAPIES CORP. Stock Exchange Release 26 May 2015 at 4.45 p.m.
Change in Biotie Therapies' Financial Calendar 2015
Biotie Therapies Corp. ("Biotie") will now publish its Interim Financial Report for:
- January to June 2015 on 20 August 2015; the previously announced date was 30 July
- January to September 2015 on 12 November 2015; the previously announced date was 29 October
Turku, 26 May 2015
Biotie Therapies Corp.
Timo Veromaa
President and CEO
For further information, please contact:
Virve Nurmi, Investor Relations Manager, Biotie Therapies Corp.
tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com
www.biotie.com
DISTRIBUTION:
NASDAQ OMX Helsinki Ltd
Main Media
About Biotie
Biotie is a specialized drug development company focused on products for neurodegenerative and psychiatric disorders. Biotie's development has delivered Selincro (nalmefene) for alcohol dependence, which received European marketing authorization in 2013 and is currently being rolled out across Europe by partner Lundbeck. The current development products include tozadenant for Parkinson's disease, which is transitioning into Phase 3 development, and two additional compounds which are in Phase 2 development for cognitive disorders including Parkinson's disease dementia, and primary sclerosing cholangitis (PSC), a rare fibrotic disease of the liver.
HUG#1923920